Delcath Systems, Inc. (NASDAQ:DCTH) Shares Acquired by Northern Trust Corp

Northern Trust Corp grew its holdings in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 57.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 100,356 shares of the company's stock after purchasing an additional 36,643 shares during the quarter. Northern Trust Corp owned approximately 0.31% of Delcath Systems worth $1,208,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Baader Bank Aktiengesellschaft purchased a new position in shares of Delcath Systems in the 4th quarter worth $204,000. Principal Financial Group Inc. raised its position in shares of Delcath Systems by 28.8% in the 4th quarter. Principal Financial Group Inc. now owns 115,183 shares of the company's stock worth $1,387,000 after buying an additional 25,736 shares during the period. Private Advisor Group LLC purchased a new position in shares of Delcath Systems in the 4th quarter worth $153,000. Charles Schwab Investment Management Inc. purchased a new position in shares of Delcath Systems in the 4th quarter worth $156,000. Finally, Quantbot Technologies LP purchased a new position in shares of Delcath Systems in the 4th quarter worth $66,000. Hedge funds and other institutional investors own 61.12% of the company's stock.

Delcath Systems Price Performance

NASDAQ DCTH traded up $0.09 during trading hours on Monday, hitting $16.30. The company had a trading volume of 491,427 shares, compared to its average volume of 378,703. Delcath Systems, Inc. has a fifty-two week low of $6.33 and a fifty-two week high of $18.23. The company has a market capitalization of $567.66 million, a price-to-earnings ratio of -12.07 and a beta of 0.72. The firm's 50 day moving average is $13.36 and its 200 day moving average is $13.27.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.07). The business had revenue of $19.80 million for the quarter, compared to analyst estimates of $16.83 million. Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. On average, equities analysts anticipate that Delcath Systems, Inc. will post -0.79 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently weighed in on DCTH. Wall Street Zen lowered Delcath Systems from a "strong-buy" rating to a "buy" rating in a research report on Sunday. HC Wainwright reiterated a "buy" rating and issued a $29.00 price target (up from $24.00) on shares of Delcath Systems in a report on Friday, May 23rd. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $24.00.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.